financetom
Business
financetom
/
Business
/
MasterBrand Q2 Adjusted Earnings Increase, Revenue Falls; Raises 2024 Adjusted Earnings Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
MasterBrand Q2 Adjusted Earnings Increase, Revenue Falls; Raises 2024 Adjusted Earnings Guidance
Aug 7, 2024 1:50 AM

04:40 AM EDT, 08/07/2024 (MT Newswires) -- MasterBrand ( MBC ) reported Q2 adjusted earnings late Tuesday of $0.45 per diluted share, up from $0.44 a year earlier.

Two analysts polled by Capital IQ expected $0.43.

Revenue for the quarter ended June 30 was $676.5 million, compared with $695.1 million a year earlier.

Two analysts surveyed by Capital IQ expected $676.1 million.

The company raised its 2024 adjusted diluted earnings per share forecast to $1.50 to $1.62 from $1.40 to $1.60 previously. Analysts surveyed by Capital IQ expect $1.54.

Price: 15.50, Change: -0.72, Percent Change: -4.44

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BillionToOne Prices $273.1 Million Upsized Initial Public Offering
BillionToOne Prices $273.1 Million Upsized Initial Public Offering
Nov 6, 2025
05:49 AM EST, 11/06/2025 (MT Newswires) -- BillionToOne ( BLLN ) said Wednesday it priced its upsized initial public offering of almost 4.6 million class A shares at $60 each, for about $273.1 million in expected gross proceeds. Underwriters have a 30-day option to purchase up to 682,665 additional shares, the company said. The shares are expected to begin trading...
AstraZeneca holds forecasts as cancer, heart drugs lift earnings
AstraZeneca holds forecasts as cancer, heart drugs lift earnings
Nov 6, 2025
(Reuters) -AstraZeneca ( AZN ) beat expectations for third quarter earnings on Thursday with strong sales of its blockbuster cancer and cardiovascular drugs, but disappointed some investors by not raising its full-year forecasts. The Anglo-Swedish drugmaker is looking to new launches, including a blood pressure drug, to offset patent expiries for medicines such as diabetes and heart treatment Farxiga as...
Deutsche Boerse and Nasdaq targeted in EU cartel probe
Deutsche Boerse and Nasdaq targeted in EU cartel probe
Nov 6, 2025
BRUSSELS (Reuters) -The European Commission on Thursday said it had opened an antitrust investigation against stock exchange companies Deutsche Boerse and Nasdaq. The Commission said it suspected the companies of breaking EU competition rules in the sector for listing, trading and clearing of financial derivatives. Deutsche Boerse and Nasdaq entities may have entered into agreements or concerted practices not to...
Deutsche Boerse and Nasdaq targeted in EU cartel probe
Deutsche Boerse and Nasdaq targeted in EU cartel probe
Nov 6, 2025
BRUSSELS, Nov 6 (Reuters) - The European Commission on Thursday said it had opened an antitrust investigation against stock exchange companies Deutsche Boerse and Nasdaq . The Commission said it suspected the companies of breaking EU competition rules in the sector for listing, trading and clearing of financial derivatives. Deutsche Boerse and Nasdaq entities may have entered into agreements or...
Copyright 2023-2026 - www.financetom.com All Rights Reserved